Squarepoint
ABUS icon

Squarepoint’s Arbutus Biopharma ABUS Stock Holding History

Squarepoint’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$999K Buy
+208,145
New +$914K ﹤0.01% 2891
2026
Q1 		– Sell
-28,775
Closed -$138K – 4192
2025
Q4 		$138K Sell
28,775
-38,836
-57% -$175K ﹤0.01% 3969
2025
Q3 		$307K Buy
67,611
+43,801
+184% +$161K ﹤0.01% 3649
2025
Q2 		$73.6K Buy
23,810
+6,454
+37% +$21.4K ﹤0.01% 4242
2025
Q1 		$60.6K Sell
17,356
-160,743
-90% -$536K ﹤0.01% 4314
2024
Q4 		$582K Buy
178,099
+113,291
+175% +$417K ﹤0.01% 3604
2024
Q3 		$250K Buy
+64,808
New +$249K ﹤0.01% 3567
2023
Q1 		– Sell
-13,650
Closed -$31.8K – 3165
2022
Q4 		$31.8K Buy
+13,650
New +$32.7K ﹤0.01% 3087
2022
Q1 		– Sell
-40,014
Closed -$156K – 2742
2021
Q4 		$156K Buy
+40,014
New +$155K ﹤0.01% 2800
2021
Q2 		– Sell
-29,880
Closed -$100K – 3161
2021
Q1 		$100K Buy
+29,880
New +$115K ﹤0.01% 2907
2020
Q3 		– Sell
-322,225
Closed -$586K – 2439
2020
Q2 		$586K Buy
322,225
+279,982
+663% +$458K 0.01% 1222
2020
Q1 		$43K Buy
+42,243
New +$114K ﹤0.01% 1729
2019
Q3 		– Sell
-65,848
Closed -$137K – 2298
2019
Q2 		$137K Buy
+65,848
New +$168K ﹤0.01% 2176
2018
Q2 		– Sell
-13,300
Closed -$67K – 1715
2018
Q1 		$67K Sell
13,300
-300
-2% -$1.59K ﹤0.01% 1602
2017
Q4 		$69K Buy
13,600
+3,300
+32% +$19.3K ﹤0.01% 1995
2017
Q3 		$64K Buy
+10,300
New +$44.1K ﹤0.01% 1549
2017
Q1 		– Sell
-13,400
Closed -$33K – 1482
2016
Q4 		$33K Buy
+13,400
New +$39K ﹤0.01% 1716

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Squarepoint's ABUS Position: Q2 2026 in Review

Squarepoint opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 208,145 shares worth $999K. The stake represents ﹤0.01% of the portfolio and ranks #2891 among its holdings. This is a return to the name: Squarepoint previously reported a position in ABUS as recently as Q4 2025.

Squarepoint first reported a position in ABUS in Q4 2016 and has held it in 17 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Squarepoint held 208,145 shares of Arbutus Biopharma worth $999K as of Q2 2026.
  • Arbutus Biopharma was a new Squarepoint position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2891 holding.
  • Squarepoint first reported a position in Arbutus Biopharma in Q4 2016 and has held it in 17 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.